Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology firm focused on rare neurological diseases, is set to participate in the 44th Annual J.P. Morgan Healthcare Conference. Company management will present an overview of Neurogene and engage in investor meetings on Wednesday, January 14, at 7:30 a.m. PT. A webcast of the presentation will be made available on the Investor Relations section of Neurogene’s website, along with a limited-time replay following the event.

Neurogene is dedicated to transforming the treatment landscape for those affected by rare neurological disorders. The company is innovating new strategies and therapies that address the shortcomings of traditional gene therapies for central nervous system conditions. Key to their approach is the advancement of their proprietary EXACT™ transgene regulation platform, which aims to deliver therapeutic levels of treatment while minimizing the toxicity often associated with standard gene therapy techniques.

Located in Houston, Texas, Neurogene boasts a state-of-the-art gene therapy manufacturing facility, designed to conduct CGMP (Current Good Manufacturing Practice) production. This facility has been instrumental in producing NGN-401, a therapy that is poised to enter pivotal clinical development. Neurogene’s commitment to advancing the efficacy and safety profiles of its treatments could play a crucial role in improving the quality of life for patients and their families grappling with these devastating conditions.

For further inquiries, the company can be reached via Mike Devine, Executive Director of Corporate Communications, or through investor relations at Argot Partners, managed by Melissa Forst. More detailed information about Neurogene’s initiatives can be found at their official website, www.neurogene.com.

Neurogene Inc. (Nasdaq: NGNE) is poised to gain significant attention following its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2024. As a clinical-stage company specializing in innovative genetic therapies for rare neurological diseases, Neurogene's presentation and subsequent investor interactions will provide critical insights into its strategic direction, technological advancements, and potential market trajectory.

Investors should note that Neurogene's mission aligns with the growing demand for effective treatments in the rare disease segment, which has been a focal point of investment in the biotechnology sector. The company's proprietary EXACT™ transgene regulation platform promises to enhance the efficacy and safety profile of gene therapies, addressing common challenges such as transgene toxicity. This technological edge could position Neurogene as a leader in a niche yet expanding market.

Furthermore, the establishment of a state-of-the-art gene therapy manufacturing facility in Houston demonstrates Neurogene's commitment to scalability and operational efficiency, vital for meeting future clinical trial demands and commercial production. The fact that NGN-401's CGMP production will support ongoing pivotal studies could indicate a crucial milestone in its journey towards regulatory approval.

As the healthcare investment landscape continues to evolve, characterized by heightened interest in innovative biotech solutions, Neurogene's developments are likely to attract significant investor scrutiny. Attending the J.P. Morgan conference can facilitate valuable relationships and partnerships, further cementing its position within the industry.

With the potential for substantive updates and clarifications regarding its pipeline and strategic vision during the conference, market participants should closely monitor Neurogene's announcements and consider it a speculative opportunity within the biotech sector. An initial investment could yield benefits as Neurogene navigates critical phases in its clinical development and market preparation.